Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares MSCI Indonesia ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while iShares MSCI Indonesia ETF trades at $12.05. Which is the better fit depends on your goals.
| AMPH | EIDO | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $19.22 |
52-Week Low | $16.87 | $10.80 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
EIDO (iShares MSCI Indonesia ETF) trades at $11.85, up 0.42% with bearish technical signals from moving averages. The ETF faces headwinds from Indonesia's monetary policy tightening and dividend cuts, while government AI initiatives and reforestation plans offer long-term growth potential. Key resistance and support cluster around $12, creating a critical price zone.
Outlook remains cautious due to currency volatility and dividend uncertainty, though structural reforms could support recovery. Risks include rupiah weakness and geopolitical factors, while institutional interest may grow if economic stability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
